MWA
GILD icon

Monograph Wealth Advisors’s Gilead Sciences GILD Stock Holding History

Monograph Wealth Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,635
Closed -$2.68M – 134
2024
Q1 		$2.68M Buy
+36,635
New +$2.82M 0.39% 29

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Monograph Wealth Advisors's GILD Position: Q2 2024 in Review

Monograph Wealth Advisors sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 36,635 shares — an estimated $2.68M sold.

Monograph Wealth Advisors first reported a position in GILD in Q1 2024 and held it in 1 quarter. The position peaked at $2.68M in Q1 2024. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

  • Monograph Wealth Advisors reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
  • Monograph Wealth Advisors sold 36,635 Gilead Sciences shares in Q2 2024, an estimated $2.68M.
  • Monograph Wealth Advisors first reported a position in Gilead Sciences in Q1 2024 and held it in 1 quarter.
  • Monograph Wealth Advisors's Gilead Sciences position peaked at $2.68M in Q1 2024.
  • 1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Monograph Wealth Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.